Holen Sie sich die Stockscreener-App
1.74
2.79%
-0.05
Handel nachbörslich:
1.75
0.01
+0.57%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.79
Offen:
$1.79
24-Stunden-Volumen:
1.12M
Relative Volume:
0.39
Marktkapitalisierung:
$269.21M
Einnahmen:
$137.74M
Nettoeinkommen (Verlust:
$-27.97M
KGV:
-10.88
EPS:
-0.16
Netto-Cashflow:
$-9.61M
1W Leistung:
+2.35%
1M Leistung:
+2.96%
6M Leistung:
-13.00%
1J Leistung:
-23.01%
1-Tages-Spanne:
$1.72
$1.80
1-Wochen-Bereich:
$1.66
$1.9099
52-Wochen-Spanne:
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
Firmenname
Heron Therapeutics Inc
Sektor
Branche
Telefon
(858) 251-4400
Adresse
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Vergleichen Sie HRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.74 | 269.21M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-23 | Eingeleitet | CapitalOne | Overweight |
| 2024-03-13 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2020-02-20 | Bestätigt | Needham | Buy |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-04-05 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2018-03-01 | Bestätigt | Needham | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Outperform |
| 2017-09-27 | Eingeleitet | Northland Capital | Outperform |
| 2017-02-27 | Eingeleitet | Needham | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-05-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-10 | Eingeleitet | Lake Street | Buy |
| 2015-09-23 | Bestätigt | Leerink Partners | Outperform |
| 2015-09-02 | Eingeleitet | BofA/Merrill | Buy |
| 2015-08-03 | Bestätigt | Brean Capital | Buy |
| 2015-06-30 | Bestätigt | JMP Securities | Mkt Outperform |
| 2015-06-19 | Bestätigt | Leerink Partners | Outperform |
| 2014-08-07 | Eingeleitet | Noble Financial | Buy |
Alle ansehen
Heron Therapeutics Inc Aktie (HRTX) Neueste Nachrichten
Heron Therapeutics (NASDAQ:HRTX) Share Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
An analyst sees good growth prospects for Heron Therapeutics Inc (HRTX) - SETE News
Financial Metrics Check: Heron Therapeutics Inc (HRTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Are Heron Therapeutics Inc (HRTX) shares a good deal now? - US Post News
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
StockNews.com Downgrades Heron Therapeutics (NASDAQ:HRTX) to Hold - MarketBeat
JPMorgan Chase & Co. Has $411,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics (NASDAQ:HRTX) Stock Rating Lowered by StockNews.com - Defense World
HRTX’s Market Whiplash: 15.03% YTD Rise, 15.03% Rise in 30 Days - The InvestChronicle
Great week for Heron Therapeutics, Inc. (NASDAQ:HRTX) institutional investors after losing 26% over the previous year - Simply Wall St
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst institutional investors who own 58% - Yahoo Finance
Heron Therapeutics (NASDAQ:HRTX) Upgraded by StockNews.com to Buy Rating - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Upgraded to Buy at StockNews.com - Defense World
Barclays PLC Purchases 50,109 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Congress Park Capital LLC Grows Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to Hold - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded to "Hold" Rating by StockNews.com - MarketBeat
San Diego Biotech Firm Heron Therapeutics Shifts Operations to North Carolina - MSN
Principal Financial Group Inc. Raises Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Geode Capital Management LLC Sells 66,974 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Jane Street Group LLC Cuts Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Franklin Resources Inc. Sells 6,304,716 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Franklin Resources Inc. Decreases Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to “Hold” at StockNews.com - Defense World
This San Diego biotech is moving its HQ to North Carolina - The San Diego Union-Tribune
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by State Street Corp - MarketBeat
Heron Therapeutics to Shift Headquarters from San Diego to Cary, - Hoodline
California public company relocates to North Carolina - The Business Journals
Heron Therapeutics Relocates Headquarters to North Carolina - TipRanks
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina - PR Newswire
Heron Therapeutics (NASDAQ:HRTX) Cut to "Hold" at StockNews.com - MarketBeat
Fmr LLC Has $859,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Verition Fund Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stake Lowered by Charles Schwab Investment Management Inc. - Defense World
U.S. District Court Upholds Validity of CINVANTI® Patents - The Eastern Progress Online
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer - The Eastern Progress Online
StockNews.com Upgrades Heron Therapeutics (NASDAQ:HRTX) to "Buy" - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.com - Defense World
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - Kilgore News Herald
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - The Eastern Progress Online
Finanzdaten der Heron Therapeutics Inc-Aktie (HRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):